Efficacy and safety of immune checkpoint inhibitor rechallenge therapy in the treatment of advanced acquired immune-resistant non-small cell lung cancer: a retrospective study.

ABSTRACT:

Background

Patients with advanced non-small cell lung cancer who have failed first-line immunotherapy and lack driver gene mutations face limited options for subsequent treatment. A working group recently proposed updated clinical diagnostic criteria for acquired immune resistance. Based on these criteria, this study evaluated the efficacy and safety of immune rechallenge therapy in patients with advanced NSCLC exhibiting acquired resistance.

Methods

The study involved 13 patients diagnosed with advanced immune-acquired resistance NSCLC. These patients initially exhibited a partial response to immunotherapy but experienced disease progression within six months following their last immune checkpoint inhibitors (ICIs) treatment. Subsequently, they received ICIs again. The outc

SUBMITTER: Wang J 

PROVIDER: S-EPMC12497850 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature